Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Inversago Pharma is a clinical-stage biopharmaceutical company, acquired by Novo Nordisk in 2023, focused on the discovery and development of next-generation, peripherally-acting CB1 receptor (CB1r) inverse agonists. These innovative therapies are designed to treat a range of metabolic disorders, including Prader-Willi syndrome (PWS), obesity, type 1 and type 2 diabetes, and diabetic nephropathy. By targeting the CB1r primarily outside the brain and spinal cord, Inversago aims to provide therapeutic benefits while minimizing centrally-mediated side effects. Their lead candidate, INV-202, is an oral CB1 inverse agonist being investigated for various metabolic conditions.
The headquarters serves as the primary center for Inversago's research and development activities, clinical program management, strategic planning, and administrative operations, now integrated within the Novo Nordisk framework.
The facility likely includes specialized laboratory spaces for biopharmaceutical research, modern office areas designed for collaboration, and essential infrastructure to support ongoing clinical development programs. Specific architectural details are not broadly publicized but are functional for a research-driven biotech.
The work culture at Inversago is rooted in scientific excellence, innovation, and a strong patient focus. It fosters collaboration and a commitment to developing impactful treatments for serious metabolic diseases, values that align with its parent company, Novo Nordisk.
Its Montréal location provides strategic access to a vibrant biotech ecosystem, including world-class academic institutions, a skilled talent pool, and a supportive network of research organizations, beneficial for its R&D objectives.
While its primary operations are based in Montréal, Canada, Inversago Pharma's clinical development activities for its drug candidates have a global scope, involving trial sites and collaborations in various countries. Since its acquisition by Novo Nordisk, Inversago's global reach and impact are significantly amplified through Novo Nordisk's extensive worldwide operational and commercial infrastructure, supporting the development and potential future distribution of its therapies.
750, boulevard Marcel-Laurin, Suite 485
Montréal
Québec
Canada
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Inversago Pharma' leadership includes:
Inversago Pharma has been backed by several prominent investors over the years, including:
The most significant executive-level event in the past 12-18 months was the acquisition by Novo Nordisk, which led to some leadership transitions. Notably, Martin D. LeBlanc, the former Chief Financial and Operating Officer, departed around the time of the acquisition in mid-2023. The core scientific and operational leadership, including CEO François Ravenelle, has largely remained to continue driving Inversago's pipeline within the new structure.
Discover the tools Inversago Pharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Inversago Pharma, like many companies in the biopharmaceutical sector, typically utilizes standardized email formats. The most common patterns observed or predicted for inversago.com are [first_initial][last]@inversago.com or [first].[last]@inversago.com.
[first_initial][last]@inversago.com
Format
fravenelle@inversago.com
Example
85%
Success rate
Endpoints News / Novo Nordisk • December 6, 2023
Novo Nordisk announced the completion of its acquisition of Inversago Pharma. This move integrates Inversago's lead investigational drug INV-202 and its CB1 receptor technology into Novo Nordisk's pipeline, aiming to develop new treatments for obesity and metabolic diseases....more
Novo Nordisk • August 10, 2023
Novo Nordisk entered into an agreement to acquire Inversago Pharma for a total consideration of up to 1.075 billion CAD. The acquisition is centered on Inversago's lead asset INV-202, an oral CB1 inverse agonist, with potential in treating metabolic disorders....more
Inversago Pharma / PR Newswire • May 2, 2023
Inversago Pharma announced the dosing of the first patient in its 'CARE' Phase 2 clinical trial for INV-202 in patients with Prader-Willi syndrome (PWS). The study aims to evaluate the efficacy, safety, and tolerability of INV-202, a peripherally-acting CB1 inverse agonist, in this rare genetic disorder characterized by metabolic disturbances....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Inversago Pharma, are just a search away.